FDA scrutinizes cancer therapies granted accelerated approvalMarch 18, 2021Breast CancerGenitourinary CancerLung CancerMultiple MyelomaOncologyHealth Policy
Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplantDecember 18, 2020Multiple MyelomaOncology
Study found dual-targeted CAR T highly active against relapsed/refractory multiple myelomaDecember 15, 2020Multiple MyelomaHematologic MalignanciesOncology
Extended virus shedding after COVID-19 in some patients with cancerDecember 10, 2020COVID-19 UpdatesMultiple MyelomaMyelodysplastic SyndromeHematologic Malignancies
Durable responses with anti-BCMA CAR T-cell for multiple myelomaDecember 6, 2020Multiple MyelomaOncology
COVID-19–related outcomes poor for patients with hematologic disease in ASH registryDecember 5, 2020COVID-19 UpdatesMultiple Myeloma
Circulating miRNA could be a potential biomarker for early diagnosis of MMNovember 24, 2020Multiple MyelomaOncologyHematologic Malignancies
Home care for bortezomib safe and reduces hospital visits in myeloma patientsNovember 11, 2020Multiple MyelomaHematologic Malignancies
Socioeconomic factors affect survival of multiple myeloma patientsOctober 22, 2020Multiple MyelomaOncologyHematologic Malignancies
Survey quantifies COVID-19’s impact on oncologySeptember 20, 2020COVID-19 UpdatesBreast CancerLung CancerGenitourinary CancerMelanomaAMLMultiple Myeloma
In-Depth Look at a Community- Based Population of Multiple Myeloma (MM) Patients Undergoing an in-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib in the United States (US) MM-6 StudySeptember 2, 2020OncologyMultiple Myeloma
Effective Pain Control With Very Low Dose Palliative Radiotherapy for Multiple Myeloma Patients With Osseous LesionsSeptember 1, 2020OncologyMultiple Myeloma
Transitioning regimen may prolong proteasome inhibitor–based therapy for MMJuly 9, 2020Multiple MyelomaOncology
